Matches in SemOpenAlex for { <https://semopenalex.org/work/W2761805493> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2761805493 endingPage "309" @default.
- W2761805493 startingPage "299" @default.
- W2761805493 abstract "Background: Mutation of EGFR is one of the most important drivers of non-small cell lung cancer. Many selective therapies take specific mutation of EGFR as target. For example, gefitinib is a commonly used front line drug for the mutations of exon 19 deletions and the L858R. New irreversible inhibitors, such as WZ4002, CO-1686, and AZD9291, are developed to overcome drug resistance caused by the acquired T790M mutation. Objective: In this study, a novel method is proposed to calculate the movement intensities of drug inhibitors relative to EGFR based on molecular dynamics (MD) simulation, in order to find the relationship of movements and drug resistances of gefitinib, WZ4002, CO-1686, and AZD9291. Method: The 4*33 complexes of four inhibitors (gefitinib, WZ4002, CO-1686 and AZD9291) with 32 common EGFR mutations as well as the wild type are analyzed. First, each EGFR-inhibitor complex is fixed to the EGFR backbone. Then each inhibitor is seen as a rigid body. Two kinds of relative movement intensities between EGFR and drug inhibitor are obtained by calculating the attitude parameter of the rigid body. Results: First, for most cases, irreversible inhibitors (WZ4002, CO-1686 and AZD9291) were observed to be more stable than reversible gefitinib, proving our method to be effective. Second, high correlation was obtained between clinical effects and the relative movement intensities. Especially for patients’ response level, the correlation P-value was observed to be 0.0462 in the best case. Conclusion: Our method represents an important contribution to molecular dynamics analysis of drug inhibitors. The analysis results of WZ4002, CO-1686 and AZD9291 are useful for drug selection for patients with specific EGFR mutation. Keywords: Epidermal growth factor receptor, non-small-cell lung cancer, molecular dynamics simulation, targeted drugs, drug response level, progression-free survival." @default.
- W2761805493 created "2017-10-20" @default.
- W2761805493 creator A5005150832 @default.
- W2761805493 creator A5008884564 @default.
- W2761805493 creator A5042683997 @default.
- W2761805493 creator A5070808098 @default.
- W2761805493 date "2018-05-03" @default.
- W2761805493 modified "2023-10-07" @default.
- W2761805493 title "Analysis of the Relative Movements Between EGFR and Drug Inhibitors Based on Molecular Dynamics Simulation" @default.
- W2761805493 doi "https://doi.org/10.2174/1574893612666171006155855" @default.
- W2761805493 hasPublicationYear "2018" @default.
- W2761805493 type Work @default.
- W2761805493 sameAs 2761805493 @default.
- W2761805493 citedByCount "4" @default.
- W2761805493 countsByYear W27618054932020 @default.
- W2761805493 countsByYear W27618054932022 @default.
- W2761805493 crossrefType "journal-article" @default.
- W2761805493 hasAuthorship W2761805493A5005150832 @default.
- W2761805493 hasAuthorship W2761805493A5008884564 @default.
- W2761805493 hasAuthorship W2761805493A5042683997 @default.
- W2761805493 hasAuthorship W2761805493A5070808098 @default.
- W2761805493 hasConcept C104317684 @default.
- W2761805493 hasConcept C121608353 @default.
- W2761805493 hasConcept C126322002 @default.
- W2761805493 hasConcept C147597530 @default.
- W2761805493 hasConcept C185592680 @default.
- W2761805493 hasConcept C2777506169 @default.
- W2761805493 hasConcept C2777930144 @default.
- W2761805493 hasConcept C2779438470 @default.
- W2761805493 hasConcept C2780035454 @default.
- W2761805493 hasConcept C2780580887 @default.
- W2761805493 hasConcept C501734568 @default.
- W2761805493 hasConcept C502942594 @default.
- W2761805493 hasConcept C55493867 @default.
- W2761805493 hasConcept C59593255 @default.
- W2761805493 hasConcept C71924100 @default.
- W2761805493 hasConcept C98274493 @default.
- W2761805493 hasConceptScore W2761805493C104317684 @default.
- W2761805493 hasConceptScore W2761805493C121608353 @default.
- W2761805493 hasConceptScore W2761805493C126322002 @default.
- W2761805493 hasConceptScore W2761805493C147597530 @default.
- W2761805493 hasConceptScore W2761805493C185592680 @default.
- W2761805493 hasConceptScore W2761805493C2777506169 @default.
- W2761805493 hasConceptScore W2761805493C2777930144 @default.
- W2761805493 hasConceptScore W2761805493C2779438470 @default.
- W2761805493 hasConceptScore W2761805493C2780035454 @default.
- W2761805493 hasConceptScore W2761805493C2780580887 @default.
- W2761805493 hasConceptScore W2761805493C501734568 @default.
- W2761805493 hasConceptScore W2761805493C502942594 @default.
- W2761805493 hasConceptScore W2761805493C55493867 @default.
- W2761805493 hasConceptScore W2761805493C59593255 @default.
- W2761805493 hasConceptScore W2761805493C71924100 @default.
- W2761805493 hasConceptScore W2761805493C98274493 @default.
- W2761805493 hasIssue "3" @default.
- W2761805493 hasLocation W27618054931 @default.
- W2761805493 hasOpenAccess W2761805493 @default.
- W2761805493 hasPrimaryLocation W27618054931 @default.
- W2761805493 hasRelatedWork W1581163092 @default.
- W2761805493 hasRelatedWork W1965001182 @default.
- W2761805493 hasRelatedWork W1983135402 @default.
- W2761805493 hasRelatedWork W1994499102 @default.
- W2761805493 hasRelatedWork W2069271031 @default.
- W2761805493 hasRelatedWork W2077501203 @default.
- W2761805493 hasRelatedWork W2098191502 @default.
- W2761805493 hasRelatedWork W2278537396 @default.
- W2761805493 hasRelatedWork W2322301907 @default.
- W2761805493 hasRelatedWork W3201960526 @default.
- W2761805493 hasVolume "13" @default.
- W2761805493 isParatext "false" @default.
- W2761805493 isRetracted "false" @default.
- W2761805493 magId "2761805493" @default.
- W2761805493 workType "article" @default.